Baidu
map

European Radiology:Gd-EOB-DTPA增强MRI放射组学对HCC组织学及患者预后的预测

2021-11-03 shaosai MedSci原创

肝细胞肝癌(HCC)是最常见的肝脏恶性肿瘤之一,是全球癌症相关死亡的第三大原因。目前,手术切除和肝移植是HCC患者的有效治疗方式,但术后复发和转移十分常见。

 肝细胞癌(HCC)是最常见的肝脏恶性肿瘤之一,是全球癌症相关死亡的第三大原因。目前,手术切除和肝移植是HCC患者的有效治疗方式,但术后复发和转移十分常见。接受肝脏切除术患者术后5年复发率约为70%,肝脏移植术的复发率为25-35%。

然而,HCC的血管生成与它的发生、发展和转移密切相关。HCC的病理性血管生成过程被称为毛细血管化。在高达90%的晚期HCC中观察到弥漫性毛细血管化的形成。最近,有专家报道了一种独特的HCC血管化模式,其特点是在病理成像中存在CD34+肿瘤包绕型血管(VETC)。VETC模式影响患者的预后,与HCC转移和复发增加有显著相关。然而,目前VETC只能通过手术切除后的组织病理学评估来诊断,术前无创预测HCC的VETC具有重要的临床意义。

Gd-EOB-DTPA是一种新肝胆特异性MRI对比剂,可以提供肝胆病变的功能和结构信息。一些研究报道,Gd-EOB-DTPA增强的MRI可以反映HCC的部分生物学特征,包括组织学等级和微血管侵袭(MVI)。放射学在HCC中的应用包括鉴别诊断、评估治愈效果和预测早期复发。据我们所知,尚未由研究使用Gd-EOB-DTPA增强MRI放射组学特征预测HCC的VETC和患者预后。

近日,发表在European Radiology杂志的一项研究根据从Gd-EOB-DTPA增强MRI中提取的瘤内和瘤周特征,开发并验证了一个放射组学模型,并评估了该模型术前预测HCC患者的VETC和预后的效能HCC患者个性化治疗方案的制定提供了参考依据

研究纳入了182名(训练队列:128;验证队列:54)接受术前Gd-EOB-DTPA增强MRI扫描的HCC患者。在肝胆图像中手动划定感兴趣的体积,包括瘤内和瘤周区域,从中提取1316个放射组学特征。使用最小绝对收缩和选择算子(LASSO)和多变量逻辑回归来选择有用的特征。使用机器学习算法建立了临床、瘤内、瘤周、联合放射组学和临床放射组学模型。采用Kaplan-Meier生存分析来评估VETC+和VETC-患者的早期复发和无进展生存(PFS)。 

在验证队列中,放射组学模型的曲线下面积(AUC)高于使用随机森林的临床模型(所有P < 0.05)。瘤周放射组学模型(AUC = 0.972;95%置信区间[CI]:0.887-0.998)的AUC明显高于瘤内模型(AUC = 0.919; 95% CI: 0.811-0.976)(p = 0.044)。在瘤内或瘤周放射学模型(PR)和联合放射学模型之间的AUC没有明显的差异(p>0.05)。早期复发和PFS在PR预测的VETC+和VETC- HCC患者之间有明显差异(P < 0.05)。PR预测的VETC是早期复发(危险比[HR]:2.08[1.31-3.28];p = 0.002)和PFS(HR:1.95[1.20-3.17];p = 0.007)的独立预测因素。 

 

 a 64岁男性,肝脏右叶、组织学证实的VETC+HCC。b 一位52岁的女性,肝脏右叶、组织学证实的VETC-HCC,在肝胆中也是低信号(白色箭头)。VETC+HCC显示肿瘤细胞群被CD34阳性内皮细胞的完整边缘所包围。VETC-HCC没有形成蜘蛛网状的血管,其内皮细胞为CD34阳性。

本研究表明,瘤内或瘤周放射组学模型在术前预测HCC的VETC和患者预后方面显示出良好的性能。与瘤内模型相比,瘤周放射组学模型的预测能力更佳。因此,本研究提示该模型有助于术前VETC预测,并协助临床医生进行治疗方案的制定

原文出处

Yixing Yu,Yanfen Fan,Ximing Wang,et al.Gd-EOB-DTPA-enhanced MRI radiomics to predict vessels encapsulating tumor clusters (VETC) and patient prognosis in hepatocellular carcinoma.DOI:10.1007/s00330-021-08250-9

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1692241, encodeId=e386169224131, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sun Jul 03 15:12:08 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729174, encodeId=a8a51e29174ba, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jun 25 13:12:08 CST 2022, time=2022-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715704, encodeId=296f1e1570486, content=<a href='/topic/show?id=8d0f1e691b5' target=_blank style='color:#2F92EE;'>#tPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17691, encryptionId=8d0f1e691b5, topicName=tPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d2632003894, createdName=循证小兵, createdTime=Wed Jun 15 18:12:08 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926296, encodeId=40d4192629617, content=<a href='/topic/show?id=9238e767680' target=_blank style='color:#2F92EE;'>#组织学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77676, encryptionId=9238e767680, topicName=组织学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Sat Dec 11 06:12:08 CST 2021, time=2021-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259549, encodeId=c3cc125954919, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Nov 05 02:12:08 CST 2021, time=2021-11-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1692241, encodeId=e386169224131, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sun Jul 03 15:12:08 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729174, encodeId=a8a51e29174ba, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jun 25 13:12:08 CST 2022, time=2022-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715704, encodeId=296f1e1570486, content=<a href='/topic/show?id=8d0f1e691b5' target=_blank style='color:#2F92EE;'>#tPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17691, encryptionId=8d0f1e691b5, topicName=tPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d2632003894, createdName=循证小兵, createdTime=Wed Jun 15 18:12:08 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926296, encodeId=40d4192629617, content=<a href='/topic/show?id=9238e767680' target=_blank style='color:#2F92EE;'>#组织学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77676, encryptionId=9238e767680, topicName=组织学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Sat Dec 11 06:12:08 CST 2021, time=2021-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259549, encodeId=c3cc125954919, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Nov 05 02:12:08 CST 2021, time=2021-11-05, status=1, ipAttribution=)]
    2022-06-25 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=1692241, encodeId=e386169224131, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sun Jul 03 15:12:08 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729174, encodeId=a8a51e29174ba, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jun 25 13:12:08 CST 2022, time=2022-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715704, encodeId=296f1e1570486, content=<a href='/topic/show?id=8d0f1e691b5' target=_blank style='color:#2F92EE;'>#tPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17691, encryptionId=8d0f1e691b5, topicName=tPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d2632003894, createdName=循证小兵, createdTime=Wed Jun 15 18:12:08 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926296, encodeId=40d4192629617, content=<a href='/topic/show?id=9238e767680' target=_blank style='color:#2F92EE;'>#组织学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77676, encryptionId=9238e767680, topicName=组织学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Sat Dec 11 06:12:08 CST 2021, time=2021-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259549, encodeId=c3cc125954919, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Nov 05 02:12:08 CST 2021, time=2021-11-05, status=1, ipAttribution=)]
    2022-06-15 循证小兵
  4. [GetPortalCommentsPageByObjectIdResponse(id=1692241, encodeId=e386169224131, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sun Jul 03 15:12:08 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729174, encodeId=a8a51e29174ba, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jun 25 13:12:08 CST 2022, time=2022-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715704, encodeId=296f1e1570486, content=<a href='/topic/show?id=8d0f1e691b5' target=_blank style='color:#2F92EE;'>#tPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17691, encryptionId=8d0f1e691b5, topicName=tPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d2632003894, createdName=循证小兵, createdTime=Wed Jun 15 18:12:08 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926296, encodeId=40d4192629617, content=<a href='/topic/show?id=9238e767680' target=_blank style='color:#2F92EE;'>#组织学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77676, encryptionId=9238e767680, topicName=组织学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Sat Dec 11 06:12:08 CST 2021, time=2021-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259549, encodeId=c3cc125954919, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Nov 05 02:12:08 CST 2021, time=2021-11-05, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1692241, encodeId=e386169224131, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sun Jul 03 15:12:08 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729174, encodeId=a8a51e29174ba, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jun 25 13:12:08 CST 2022, time=2022-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715704, encodeId=296f1e1570486, content=<a href='/topic/show?id=8d0f1e691b5' target=_blank style='color:#2F92EE;'>#tPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17691, encryptionId=8d0f1e691b5, topicName=tPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d2632003894, createdName=循证小兵, createdTime=Wed Jun 15 18:12:08 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926296, encodeId=40d4192629617, content=<a href='/topic/show?id=9238e767680' target=_blank style='color:#2F92EE;'>#组织学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77676, encryptionId=9238e767680, topicName=组织学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Sat Dec 11 06:12:08 CST 2021, time=2021-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259549, encodeId=c3cc125954919, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Nov 05 02:12:08 CST 2021, time=2021-11-05, status=1, ipAttribution=)]
    2021-11-05 仁医06

相关资讯

Radiology:在预测HCC微血管浸润方面,MR并非想象中的可靠!

众所周知,微血管浸润(MVI)是肝细胞肝癌(HCC)外科切除或肝移植后的主要预后因素,在开始治疗之前准确预测HCC的MVI对临床制定正确的治疗方案非常重要。

Radiology:这究竟是不是肿瘤存活?只需多这一步,使LI-RADS治疗反应算法更准确!

越来越多肝细胞肝癌(HCC)患者接受局部治疗(LRT),包括射频消融和经导管动脉化疗栓塞,以作为一线或二线治疗和肝切除或肝移植(LT)的桥梁。

Radiology:MRI,让增殖型HCC“一眼到底”!

众所周知,肝细胞肝癌(HCC)在基因组、分子和组织学层面的异质性较强。越来越多的证据表明,分子和组织形态学特征之间的相关性,导致了HCC的几种组织学变体的提出。

Br J Cancer:SLC38A4调控Wnt/β-catenin/MYC/HMGCS2信号通路抑制肝细胞癌的发生发展

肝癌作为全球第六大常见癌症,也是全球癌症相关死亡的第三大原因。

Cell Death Dis:BH3-only蛋白表达水平决定肝细胞癌患者对基于索拉非尼的药物组合治疗的反应

肝细胞癌(HCC)是一个严重的全球健康问题,该疾病的发病率逐年增加且治疗选择有限。

Br J Cancer:晚期肝细胞癌患者诊断性活检的可行性分析

早在2001年欧洲肝脏研究协会(EASL)首次定义了用于诊断肝细胞癌(HCC)的无创放射学标准(NIRC),并随着时间的推移不断的完善该标准。

Baidu
map
Baidu
map
Baidu
map